Total US direct-to-consumer advertising spending for prescriptionpharmaceuticals reached $146 million in April 1998, up 38% over April 1997, says Scott-Levin's Direct-To-Consumer Advertising Audit, which notes that, year-to-date, total DTC ad spending came to just under $400 million. The data mean that DTC spending will hit the $1 billion-plus mark for the second year in a row, it was noted.
Television continued as the fastest-growing medium for DTC ads, generating 55% of the total in April compared to 26% in April 1997. Second and third this April were magazines, on 32%, and newspaper promotion, at 12%.
Bristol-Myers Squibb topped all drug companies in DTC ad spending, with over $27 million in April; $24.6 million was allocated to Pravachol (pravastatin) alone. Glaxo Wellcome ranked second, spending $23.8 million, followed by Schering-Plough at $22.1 million, Zeneca at $12.8 million and Pfizer at $10.6 million. The top five products for DTC ad spending in April were Pravachol, Claritin (loratadine) on $22 million, Zyrtec (cetirizine) on $9.1 million and Zyban (bupropion) and Flonase (fluticasone), both $8.1 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze